JP2009509168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009509168A5 JP2009509168A5 JP2008532319A JP2008532319A JP2009509168A5 JP 2009509168 A5 JP2009509168 A5 JP 2009509168A5 JP 2008532319 A JP2008532319 A JP 2008532319A JP 2008532319 A JP2008532319 A JP 2008532319A JP 2009509168 A5 JP2009509168 A5 JP 2009509168A5
- Authority
- JP
- Japan
- Prior art keywords
- igf
- tumor cell
- kinase inhibitor
- tumor
- inhibition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims 34
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 33
- 210000004881 tumor cells Anatomy 0.000 claims 26
- 230000002401 inhibitory effect Effects 0.000 claims 16
- 230000035945 sensitivity Effects 0.000 claims 16
- 230000001613 neoplastic Effects 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 230000004565 tumor cell growth Effects 0.000 claims 9
- 108010067306 Fibronectins Proteins 0.000 claims 6
- 102000016359 Fibronectins Human genes 0.000 claims 6
- 230000037320 fibronectin Effects 0.000 claims 6
- 102100004728 CDH1 Human genes 0.000 claims 5
- 101700016900 CDH1 Proteins 0.000 claims 5
- 101710040918 shg Proteins 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 102000013127 Vimentin Human genes 0.000 claims 3
- 108010065472 Vimentin Proteins 0.000 claims 3
- 108010084448 gamma Catenin Proteins 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 102100005399 NHLH1 Human genes 0.000 claims 2
- 101710007431 NHLH1 Proteins 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 229960005188 collagen Drugs 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 108090000020 Alpha-catenin Proteins 0.000 claims 1
- 102000003730 Alpha-catenin Human genes 0.000 claims 1
- 208000000409 Breast Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- -1 Brk Proteins 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 102100009074 FBN1 Human genes 0.000 claims 1
- 102100009080 FBN2 Human genes 0.000 claims 1
- 108010030229 Fibrillin-1 Proteins 0.000 claims 1
- 108010030242 Fibrillin-2 Proteins 0.000 claims 1
- 102100013423 KRT8 Human genes 0.000 claims 1
- 102000018329 Keratin-18 Human genes 0.000 claims 1
- 108010066327 Keratin-18 Proteins 0.000 claims 1
- 108010070511 Keratin-8 Proteins 0.000 claims 1
- 101700042923 LOXL1 Proteins 0.000 claims 1
- 102100015592 LOXL1 Human genes 0.000 claims 1
- 102100019106 MYRF Human genes 0.000 claims 1
- 101700074621 MYRF Proteins 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- 102000008789 N-cadherin Human genes 0.000 claims 1
- 108050000637 N-cadherin Proteins 0.000 claims 1
- 102000007000 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 108010008217 nidogen Proteins 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (21)
- 腫瘍細胞によって発現された上皮バイオマーカーのレベルを評価すること、および
IGF−1Rキナーゼ阻害剤による阻害に対する腫瘍細胞増殖の感受性を予測することを含み、
腫瘍細胞による上皮バイオマーカー発現の高いレベルは、IGF−1Rキナーゼ阻害剤による阻害に対する高い感受性と相関する、
IGF−1Rキナーゼ阻害剤による阻害に対する腫瘍細胞増殖の感受性を予測する方法。 - 上皮バイオマーカーが、E−カドヘリン、Brk、γ−カテニン、α−カテニン、ケラチン8およびケラチン18から選択される、請求項1に記載の方法。
- 腫瘍細胞によって発現された間葉バイオマーカーのレベルを評価すること、および
IGF−1Rキナーゼ阻害剤による阻害に対する腫瘍細胞増殖の感受性を予測することを含み、
腫瘍細胞による間葉バイオマーカー発現の高いレベルは、IGF−1Rキナーゼ阻害剤による阻害に対する低い感受性と相関する、
IGF−1Rキナーゼ阻害剤による阻害に対する腫瘍細胞増殖の感受性を予測する方法。 - 間葉バイオマーカーが、ビメンチン、フィブロネクチン、フィブリリン−1、フィブリリン−2、コラーゲンアルファ−2(IV)、コラーゲンアルファ−2(V)、LOXL1、ニドジェン、C11orf9、テネイシン、N−カドヘリンおよび胚性EDB+フィブロネクチンから選択される、請求項3に記載の方法。
- 腫瘍細胞によって発現された1つ以上の上皮バイオマーカーのレベルを評価すること、および
IGF−1Rキナーゼ阻害剤による阻害に対する腫瘍細胞増殖の感受性を予測することを含み、
評価された腫瘍細胞上皮バイオマーカーの全ての同時の高い発現レベルは、IGF−1Rキナーゼ阻害剤による阻害に対する高い感受性と相関する、
IGF−1Rキナーゼ阻害剤による阻害に対する腫瘍細胞増殖の感受性を予測する方法。 - 1つ以上の上皮バイオマーカーが、E−カドヘリンおよびBrkを含む、請求項5に記載の方法。
- 1つ以上の上皮バイオマーカーが、E−カドヘリンおよびγ−カテニンを含む、請求項5に記載の方法。
- 腫瘍細胞によって発現された1つ以上の間葉バイオマーカーのレベルを評価すること、および
IGF−1Rキナーゼ阻害剤による阻害に対する腫瘍細胞増殖の感受性を予測することを含み、
評価された腫瘍細胞間葉バイオマーカーの全ての同時の低い発現レベル又は検出不能な発現レベルが、IGF−1Rキナーゼ阻害剤による阻害に対する高い感受性と相関する、
IGF−1Rキナーゼ阻害剤による阻害に対する腫瘍細胞増殖の感受性を予測する方法。 - 1つ以上の間葉バイオマーカーが、ビメンチンおよびフィブロネクチンを含む、請求項8に記載の方法。
- 腫瘍細胞によって発現される上皮バイオマーカーのレベルを評価すること、
腫瘍細胞によって発現される間葉バイオマーカーのレベルを評価すること、および
IGF−1Rキナーゼ阻害剤による阻害に対する腫瘍細胞増殖の感受性を予測することを含み、
上皮バイオマーカー発現レベルと間葉バイオマーカー発現レベルとの高い比が、IGF−1Rキナーゼ阻害剤による阻害に対する高い感受性と相関する、
IGF−1Rキナーゼ阻害剤による阻害に対する腫瘍細胞増殖の感受性を予測する方法。 - 上皮バイオマーカーがE−カドヘリンを含み、および間葉バイオマーカーがフィブロネクチンを含む、請求項10に記載の方法。
- 上皮バイオマーカーがBrkを含み、および間葉バイオマーカーがフィブロネクチンを含む、請求項10に記載の方法。
- 上皮バイオマーカーがE−カドヘリンを含み、および間葉バイオマーカーがビメンチンを含む、請求項10に記載の方法。
- 上皮バイオマーカーがγ−カテニンを含み、および間葉バイオマーカーがフィブロネクチンを含む、請求項10に記載の方法。
- 患者における腫瘍または腫瘍転移を治療するために使用するIGF−1Rキナーゼ阻害剤であって、IGF−1Rキナーゼ阻害剤に対する患者の応答の可能性が、腫瘍細胞が上皮−間葉遷移を起こしたかどうかを評価することによって診断されている、前記IGF−1Rキナーゼ阻害剤。
- 1つ以上の追加の抗癌剤が、IGF−1Rキナーゼ阻害剤と同時又は順次に共投与される、請求項15に記載する使用のためのIGF−1Rキナーゼ阻害剤。
- (a)新生物症状を有する患者から得た新生物細胞含有試料中の候補上皮バイオマーカーのレベルを測定すること、および
(b)前記患者から得た前記試料中の前記候補上皮バイオマーカーのレベルと、IGF−1Rキナーゼ阻害剤による前記新生物症状の治療の有効性との間の相関を特定することを含み、
上皮バイオマーカーの高いレベルとIGF−1Rキナーゼ阻害剤による新生物症状のさらに有効な治療との相関が、前記上皮バイオマーカーがIGF−1Rキナーゼ阻害剤による新生物症状のさらに有効な治療に対する診断指標であることを示す、IGF−1Rキナーゼ阻害剤での新生物症状のさらに有効な治療に対する診断指標である上皮バイオマーカーを同定する方法。 - (a)新生物症状を有する患者から得た新生物細胞含有試料中の候補間葉バイオマーカーのレベルを測定すること、および
(b)前記患者から得た前記試料中の前記候補間葉バイオマーカーのレベルと、IGF−1Rキナーゼ阻害剤による前記新生物症状の治療の有効性との間の相関を特定することを含み、
間葉バイオマーカーの高いレベルとIGF−1Rキナーゼ阻害剤による新生物症状のより低い有効性の治療との相関が、前記間葉バイオマーカーがIGF−1Rキナーゼ阻害剤による新生物症状のより低い有効性の治療に対する診断指標である、IGF−1Rキナーゼ阻害剤での新生物症状のより低い有効性の治療に対する診断指標である間葉バイオマーカーを同定する方法。 - 腫瘍細胞が、以前に上皮−間葉遷移した腫瘍細胞として特徴づけられ、前記腫瘍細胞の試料をIGF−1Rキナーゼ阻害剤と接触させること、前記腫瘍細胞の同一試料を試験薬剤の存在下でIGF−1Rキナーゼ阻害剤と接触させること、IGF−1Rキナーゼ阻害剤によって媒介される増殖阻害を試験薬剤の存在下と非存在下で比較すること、並びに試験薬剤がIGF−1Rキナーゼ阻害剤に対する腫瘍細胞増殖の感受性を高める薬剤であるかどうかを判定することを含む、IGF−1Rキナーゼ阻害剤に対する腫瘍細胞増殖の感受性を高める薬剤を同定する方法。
- 腫瘍細胞または腫瘍が、NSCL腫瘍細胞または腫瘍、結腸腫瘍細胞または腫瘍、乳房腫瘍細胞または腫瘍、頭頸部腫瘍細胞または腫瘍、或いは膵臓腫瘍細胞または腫瘍である、請求項1、3、5、8または10に記載の方法、或いは請求項15に記載の使用。
- 腫瘍細胞または腫瘍が、NSCL腫瘍細胞または腫瘍である、請求項20に記載の方法または使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71864305P | 2005-09-20 | 2005-09-20 | |
US60/718,643 | 2005-09-20 | ||
PCT/US2006/036502 WO2007035744A1 (en) | 2005-09-20 | 2006-09-19 | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009509168A JP2009509168A (ja) | 2009-03-05 |
JP2009509168A5 true JP2009509168A5 (ja) | 2009-11-05 |
JP5055284B2 JP5055284B2 (ja) | 2012-10-24 |
Family
ID=37685099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008532319A Expired - Fee Related JP5055284B2 (ja) | 2005-09-20 | 2006-09-19 | インシュリン様成長因子−1受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー |
Country Status (9)
Country | Link |
---|---|
US (2) | US8062838B2 (ja) |
EP (2) | EP1926996B1 (ja) |
JP (1) | JP5055284B2 (ja) |
AT (1) | ATE533057T1 (ja) |
AU (1) | AU2006292278B2 (ja) |
CA (1) | CA2623125A1 (ja) |
DK (1) | DK1926996T3 (ja) |
ES (1) | ES2374450T3 (ja) |
WO (1) | WO2007035744A1 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
CA2601157A1 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
ES2374450T3 (es) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
WO2007147074A2 (en) | 2006-06-14 | 2007-12-21 | Living Microsystems, Inc. | Use of highly parallel snp genotyping for fetal diagnosis |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
WO2008109075A2 (en) * | 2007-03-05 | 2008-09-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
EP2134860A1 (en) | 2007-04-13 | 2009-12-23 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to kinase inhibitors |
EP2537529B1 (en) | 2007-08-02 | 2018-10-17 | Gilead Biologics, Inc. | Loxl2 inhibitory antibodies and uses thereof |
US7939272B2 (en) * | 2007-10-03 | 2011-05-10 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US8048621B2 (en) * | 2007-10-03 | 2011-11-01 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
CA2709827A1 (en) * | 2007-12-18 | 2009-06-25 | Schering Corporation | Biomarkers for sensitivity to anti-igf1r therapy |
EP2271941B1 (en) * | 2008-03-07 | 2012-08-08 | OSI Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2009126310A2 (en) * | 2008-04-10 | 2009-10-15 | Massachusetts Institute Of Technology | Methods for identification and use of agents targeting cancer stem cells |
WO2010022268A2 (en) * | 2008-08-20 | 2010-02-25 | The Regents Of The University Of Colorado, A Body Corporate | Markers for assessing the susceptibility of cancer to igf-1r treatment |
CA3069081C (en) | 2008-09-20 | 2023-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
WO2010048123A2 (en) * | 2008-10-20 | 2010-04-29 | Eckhardt S Gail | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
MX2011004824A (es) * | 2008-11-07 | 2012-01-12 | Triact Therapeutics Inc | Uso de derivados de butano catecólico en terapia contra el cáncer. |
US20110171124A1 (en) * | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
US8465912B2 (en) * | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099363A1 (en) * | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010120599A2 (en) * | 2009-04-16 | 2010-10-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
WO2010120966A1 (en) * | 2009-04-17 | 2010-10-21 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
EP2519826A2 (en) | 2010-03-03 | 2012-11-07 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US8621235B2 (en) | 2011-01-06 | 2013-12-31 | Verifone, Inc. | Secure pin entry device |
EP2671082B1 (en) | 2011-02-02 | 2020-01-15 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2012167278A1 (en) | 2011-06-02 | 2012-12-06 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
WO2014074805A1 (en) | 2012-11-08 | 2014-05-15 | Whitehead Institute For Biomedical Research | Selective targeting of cancer stem cells |
JP2015536667A (ja) | 2012-12-03 | 2015-12-24 | アルマック・ダイアグノスティクス・リミテッドAlmac Diagnostics Limited | 癌のための分子診断検査 |
US9834575B2 (en) | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
CA2923667A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
US10398672B2 (en) | 2014-04-29 | 2019-09-03 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
CN108680745B (zh) * | 2018-01-03 | 2021-06-15 | 湖州市中心医院 | 血清脂质生物标志物在nsclc早期诊断中的应用方法 |
CN111638345A (zh) * | 2020-07-01 | 2020-09-08 | 山东凯歌智能机器有限公司 | 检测非小细胞肺癌患者外周血循环肿瘤细胞E-Cadherin基因突变的试剂盒及方法 |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4503035B1 (en) | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
JPH07133280A (ja) | 1993-11-09 | 1995-05-23 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
DK0821671T3 (da) | 1995-04-20 | 2001-04-23 | Pfizer | Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
CN1202932A (zh) | 1995-10-23 | 1998-12-23 | 儿童医学中心公司 | 治疗用抗血管生成的组合物和方法 |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
JPH11512750A (ja) | 1996-06-27 | 1999-11-02 | ファイザー インク. | 2―(2―オキソ―エチリデン)―イミダゾリジン―4―オンの誘導体およびファルネシル蛋白質トランスフェラーゼ阻害物質としてのそれらの使用法 |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
ATE217315T1 (de) | 1996-07-18 | 2002-05-15 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
ATE272640T1 (de) | 1997-01-06 | 2004-08-15 | Pfizer | Cyclische sulfonderivate |
PT977733E (pt) | 1997-02-03 | 2003-12-31 | Pfizer Prod Inc | Derivados de acido arilsulfonilamino-hidroxamico |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
ES2239393T3 (es) | 1997-05-07 | 2005-09-16 | Sugen, Inc. | Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa. |
JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
HUP0002960A3 (en) | 1997-08-08 | 2001-12-28 | Pfizer Prod Inc | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
CN101328186A (zh) | 1997-11-11 | 2008-12-24 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
JPH11236333A (ja) | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−4−オン誘導体 |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
CA2332331A1 (en) | 1998-05-15 | 1999-11-25 | Francisco Robert | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
US6395734B1 (en) | 1998-05-29 | 2002-05-28 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
ES2237125T3 (es) | 1998-08-27 | 2005-07-16 | Pfizer Products Inc. | Derivados de quinolin-2-ona utiles como agentes anticancerigenos. |
JP3495706B2 (ja) | 1998-08-27 | 2004-02-09 | ファイザー・プロダクツ・インク | 抗癌薬として有用なアルキニル置換キノリン−2−オン誘導体 |
US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
JP2002526500A (ja) | 1998-09-18 | 2002-08-20 | ビーエーエスエフ アクチェンゲゼルシャフト | プロテインキナーゼ阻害剤としてのピロロピリミジン |
EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
EP1006184A1 (en) * | 1998-12-03 | 2000-06-07 | F. Hoffmann-La Roche Ag | IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof |
US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
WO2000035455A1 (en) | 1998-12-15 | 2000-06-22 | Telik, Inc. | Heteroaryl-aryl ureas as igf-1 receptor antagonists |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
EP1150973B1 (en) | 1999-02-11 | 2005-06-15 | Pfizer Products Inc. | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
ES2328269T3 (es) | 1999-05-21 | 2009-11-11 | Bristol-Myers Squibb Company | Pirrolotriazinas como inhibires de quinasas. |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
DE60008206T2 (de) | 1999-11-30 | 2004-12-02 | Pfizer Products Inc., Groton | Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase |
US6448086B1 (en) | 2000-01-18 | 2002-09-10 | Diagnostic Systems Laboratories, Inc. | Insulin-like growth factor system and cancer |
HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
NZ531378A (en) | 2001-09-19 | 2006-11-30 | Aventis Pharma S | Indolizines as kinase protein inhibitors suitable for treating solid tumours |
AU2002348020A1 (en) | 2001-10-25 | 2003-05-06 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
WO2003035614A2 (en) | 2001-10-25 | 2003-05-01 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AU2002348394A1 (en) | 2001-10-25 | 2003-05-06 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
WO2003035619A1 (en) | 2001-10-25 | 2003-05-01 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
EP1534739A4 (en) | 2002-01-18 | 2006-05-31 | Bristol Myers Squibb Co | IDENTIFICATION OF POLYNUCLEOTIDES AND POLYPEPTIDES FOR PREDICTING THE ACTIVITY OF COMPOUNDS THAT INTERACT WITH TYROSINE KINASE PROTEINS AND / OR TYROSINE KINASE PROTEIN PATHWAYS |
CN100591355C (zh) | 2002-02-14 | 2010-02-24 | 达纳-法伯癌症研究公司 | 治疗过度增殖疾病的组合物及其制药用途 |
NZ571508A (en) | 2002-05-24 | 2010-05-28 | Schering Corp | Neutralizing human anti-IGFR antibody |
US20040132097A1 (en) | 2002-06-19 | 2004-07-08 | Bacus Sarah S. | Method for predicting response to epidermal growth factor receptor-directed therapy |
US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
JP4606879B2 (ja) | 2002-11-15 | 2011-01-05 | ジェノミック ヘルス, インコーポレイテッド | Egfr陽性癌の遺伝子発現プロファイリング |
WO2004063709A2 (en) | 2003-01-08 | 2004-07-29 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
EP1590487A2 (en) | 2003-02-06 | 2005-11-02 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
WO2004086038A2 (en) | 2003-03-28 | 2004-10-07 | Institut Curie | A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active akt |
WO2004111273A2 (en) | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
JP2007516693A (ja) * | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
JP2006528631A (ja) | 2003-07-24 | 2006-12-21 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
EP1664716A4 (en) | 2003-08-15 | 2008-08-13 | Smithkline Beecham Corp | CANCER BIOMARKERS |
CN1898240B (zh) | 2003-10-15 | 2011-08-03 | Osi制药公司 | 咪唑并吡嗪类酪氨酸激酶抑制剂 |
TW200526684A (en) | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
WO2005070020A2 (en) | 2004-01-23 | 2005-08-04 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
US20080113874A1 (en) | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
WO2005121380A1 (en) | 2004-06-04 | 2005-12-22 | Smithkline Beecham Corporation | Predictive biomarkers in cancer therapy |
EP1802341A1 (en) | 2004-07-16 | 2007-07-04 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
FR2875601B1 (fr) | 2004-09-17 | 2007-04-13 | Genome Express S A Sa | Vimentine phosphorylee comme marqueur de l'agressivite et/ou l'invasivite des tumeurs |
US7811562B2 (en) | 2004-12-03 | 2010-10-12 | Schering Corporation | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
CA2601157A1 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
ES2374450T3 (es) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
PT2027470E (pt) | 2006-06-02 | 2013-01-28 | Pfizer Prod Inc | Ensaio de células tumorais circulantes |
WO2008019375A2 (en) | 2006-08-07 | 2008-02-14 | The Board Of Regents Of The University Of Texas System | Proteomic patterns of cancer prognostic and predictive signatures |
WO2008070460A2 (en) | 2006-11-27 | 2008-06-12 | The Regents Of The University Of California | The use of soluble e-cadherin as a novel serum marker |
-
2006
- 2006-09-19 ES ES06814954T patent/ES2374450T3/es active Active
- 2006-09-19 WO PCT/US2006/036502 patent/WO2007035744A1/en active Application Filing
- 2006-09-19 US US11/523,259 patent/US8062838B2/en not_active Expired - Fee Related
- 2006-09-19 CA CA002623125A patent/CA2623125A1/en not_active Abandoned
- 2006-09-19 AT AT06814954T patent/ATE533057T1/de active
- 2006-09-19 DK DK06814954.1T patent/DK1926996T3/da active
- 2006-09-19 AU AU2006292278A patent/AU2006292278B2/en not_active Ceased
- 2006-09-19 EP EP06814954A patent/EP1926996B1/en active Active
- 2006-09-19 EP EP11166119A patent/EP2372363A1/en not_active Withdrawn
- 2006-09-19 JP JP2008532319A patent/JP5055284B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-11 US US13/294,213 patent/US8388957B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009509168A5 (ja) | ||
Demicco et al. | Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model | |
Adler et al. | Metastatic pathways in patients with cutaneous melanoma | |
JP2017503488A5 (ja) | ||
JP2015505370A5 (ja) | ||
DE602006016085D1 (de) | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor | |
BR112013000869A2 (pt) | método para diagnóstico de câncer de próstata (pca) com uma sensibilidade desejada em um sujeito; método para monitorar a progressão do câncer de próstata (pca) em um sujeito; método para avaliar se um sujeito tem que ser submetido a uma biópsia de próstata; kit compreendendo um primeiro componente e, opcionalmente, um segundo componente e uso de um kit | |
JP2011526693A5 (ja) | ||
Cichon et al. | Growth of lung cancer cells in three-dimensional microenvironments reveals key features of tumor malignancy | |
BR112012019542A2 (pt) | "método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit" | |
MX2010010465A (es) | Metodo para la deteccion de igf1r/chr 15 en celulas tumorales circulantes mediante hibridacion fluorescente in situ. | |
WO2010005991A3 (en) | Circulating tumor and tumor stem cell detection using genomic specific probes | |
Luo et al. | An ADAM12 and FAK positive feedback loop amplifies the interaction signal of tumor cells with extracellular matrix to promote esophageal cancer metastasis | |
GB0524110D0 (en) | Biomarkers and methods for identification of agents useful in the treatment of affective disorders | |
WO2018102775A1 (en) | Methods and kits for predicting cancer prognosis and metastasis | |
WO2008109075A3 (en) | Biomarkers and methods for determining sensitivity to ctla-4 antagonists | |
Diaz‐Romero et al. | S100A1 and S100B expression patterns identify differentiation status of human articular chondrocytes | |
Zhou et al. | Expression of RECK and MMP‑2 in salivary adenoid cystic carcinoma: Correlation with tumor progression and patient prognosis | |
Zhan et al. | A three‐gene signature from protein–protein interaction network of LOXL 2‐and actin‐related proteins for esophageal squamous cell carcinoma prognosis | |
RU2014108986A (ru) | Прогностические факторы для лечения рака | |
JP2010096748A5 (ja) | ||
Gong et al. | Loss of lamin A but not lamin C expression in epithelial ovarian cancer cells is associated with metastasis and poor prognosis | |
ATE495439T1 (de) | Punktquellendiffusionszellaktivitätstestvorrich unen und -verfahren | |
Seidel et al. | A multidimensional impedance platform for the real-time analysis of single and combination drug pharmacology in patient-derived viable melanoma models | |
Zhuo et al. | Overexpression of N-cadherin is correlated with metastasis and worse survival in colorectal cancer patients |